PharmaPoint: Prostate Cancer - Germany Drug Forecast and Market Analysis to 2022
Dec 31, 2012 - GlobalData - 161 pages
Abstract Table of Contents Request Details Related
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
4.3 Germany
4.3.1 Diagnosis
4.3.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands, Hormone Therapies
5.3.1 Zoladex (goserelin acetate)
5.3.2 Lupron Depot (leuprolide acetate)
5.3.3 Eligard (leuprolide acetate)
5.3.4 Trelstar (triptorelin acetate)
5.3.5 Firmagon (degarelix)
5.3.6 Casodex (bicalutamide)
5.4 Product Profiles - Major Brands, Chemotherapies
5.4.1 Taxotere (docetaxel)
5.4.2 Jevtana (cabazitaxel)
5.5 Product Profiles - Major Brands, Therapeutic Vaccines
5.5.1 Provenge (sipuleucil-T)
5.6 Product Profiles - Major Brands, Targeted Therapies
5.6.1 Zytiga (abiraterone acetate)
5.6.2 Xtandi (enzalutamide)
5.7 Product Profiles - Major Brands, Bone Therapies
5.7.1 Xgeva (denosumab)
5.7.2 Zometa (zoledronic acid)
5.8 Other Marketed Hormone and Drug Therapies
6 Opportunity and Unmet Need
6.1 Overview
6.2 Efficacy at Prolonging Overall Survival
6.3 Safety
6.4 Mitigation of Symptoms
6.5 Cost
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cabozantinib
7.2.2 Custirsen Sodium
7.2.3 Sprycel (dasatinib)
7.2.4 Yervoy (ipilimumab)
7.2.5 Orteronel
7.2.6 Alpharadin (radium-223 chloride)
7.2.7 Tasquinimod
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM)
8 Market Outlook
8.1 Germany
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment
9.4.2 Percent Drug-treated Patients
9.4.3 Percent Hormone Therapy-Treated Patients
9.4.4 Drugs Included in Each Therapeutic Class
9.4.5 Launch, Patent and Market Exclusivity Expiry Dates
9.4.6 General Pricing Assumptions
9.4.7 Individual Drug Assumptions
9.4.8 Generic Erosion
9.4.9 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets
Table 2: Global Variations in Recommendations on Routine PSA Screening
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012
Table 5: Leading Treatments for Prostate Cancer, 2012
Table 6: Product Profile - Zoladex
Table 7: Zoladex SWOT Analysis, 2012
Table 8: Product Profile - Lupron Depot
Table 9: Lupron Depot SWOT Analysis, 2012
Table 10: Product Profile - Eligard
Table 11: Eligard SWOT Analysis, 2012
Table 12: Product Profile - Trelstar
Table 13: Trelstar SWOT Analysis, 2012
Table 14: Product Profile - Firmagon
Table 15: Firmagon SWOT Analysis, 2012
Table 16: Product Profile - Casodex
Table 17: Casodex SWOT Analysis, 2012
Table 18: Product Profile - Taxotere
Table 19: Taxotere SWOT Analysis, 2012
Table 20: Product Profile - Jevtana
Table 21: Jevtana SWOT Analysis, 2012
Table 22: Product Profile - Provenge
Table 23: Provenge SWOT Analysis, 2012
Table 24: Product Profile - Zytiga
Table 25: Zytiga SWOT Analysis, 2012
Table 26: Product Profile - Xtandi
Table 27: Xtandi SWOT Analysis, 2012
Table 28: Product Profile - Xgeva
Table 29: Xgeva SWOT Analysis, 2012
Table 30: Product Profile - Zometa
Table 31: Zometa SWOT Analysis, 2012
Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012
Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment
Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment
Table 35: Clinical Unmet Needs - Gap Analysis, 2012
Table 36: Prostate Cancer - Phase III Pipeline, 2012
Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012
Table 38: Product Profile - Cabozantinib
Table 39: Cabozantinib SWOT Analysis, 2012
Table 40: Product Profile - Custirsen Sodium
Table 41: Custirsen Sodium SWOT Analysis, 2012
Table 42: Product Profile - Sprycel
Table 43: Sprycel SWOT Analysis, 2012
Table 44: Product Profile - Yervoy
Table 45: Yervoy SWOT Analysis, 2012
Table 46: Product Profile - Orteronel
Table 47: Orteronel SWOT Analysis, 2012
Table 48: Product Profile - Alpharadin (radium-223 chloride)
Table 49: Alpharadin SWOT Analysis, 2012
Table 50: Product Profile - Tasquinimod
Table 51: Tasquinimod SWOT Analysis, 2012
Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM)
Table 53: ProstVac SWOT Analysis, 2012
Table 54: Sales Forecasts ($m) for Prostate Cancer in Germany, 2012-2022
Table 55: Key Events Impacting Sales for Prostate Cancer in Germany, 2012-2022
Table 56: Prostate Cancer Market in Germany - Drivers and Barriers, 2012
Table 57: Key Launch Dates
Table 58: Key Patent Expiries and Market Exclusivity Expiries
Table 59: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022
Figure 3: Sales for Prostate Cancer in Germany by Drug Class, 2012-2022

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.